Drug Trial Radar · NCT05965817
Fluorescence-guided Resection Of Colorectal Liver Metastases Using SGM-101 and Indocyanine GREEN
Last checked: Nov 19, 2026Latest source record: May 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
10
Planned (sponsor's estimate)
Start
Dec 1, 2023
Primary completion
Mar 1, 2025
Study completion May 1, 2025
Sponsor
- Lead sponsor
- Leiden University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be the first trial testing the feasibility of working simultaneously with the two fluorescent dyes ICG and SGM-101 in 10 patients with colorectal metastases.
Conditions
- Colorectal Cancer
- Liver Metastasis Colon Cancer
- Image
Interventions
SGM-101 op top of ICGDrug
SGM-101 op top of ICG
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the feasibility of simultaneous use of ICG and SGM-101 for intraoperative imaging of colorectal liver metastases.Time frame: 1.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Leiden University Medical Center
Leiden, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.